HC Wainwright Has Lowered Expectations for Outlook Therapeutics (NASDAQ:OTLK) Stock Price

Outlook Therapeutics (NASDAQ:OTLK – Free Report) had its price objective reduced by HC Wainwright from $30.00 to $3.00 in a report published on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock. OTLK has been the topic of a number of other reports. Chardan Capital reiterated a “neutral” rating on shares of […]

Leave a Reply

Your email address will not be published.

Previous post Global Blockchain Acquisition Corp. (NASDAQ:GBBK) Sees Significant Drop in Short Interest
Next post HC Wainwright Reiterates “Buy” Rating for OKYO Pharma (NASDAQ:OKYO)